The Shanghai Institute of Materia Medica of the Chinese Academy of Sciences has discovered glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of type 2 diabetes and obesity, among others.
The University of Florida has prepared and tested PPARγ agonists reported to be useful for the treatment of diabetes, hyperparathyroidism, metabolic syndrome, multiple myeloma, nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH), obesity, osteoporosis and Paget disease, among others.
Zyversa Therapeutics Inc. announced it has selected obesity and its related metabolic complications as the lead indication for its ASC protein inhibitor IC-100. One consequence of high weight is chronic inflammation, which increases the risk of multiple metabolic and cardiovascular disorders.
Scientists at Boehringer Ingelheim GmbH have made the ketohexokinase (KHK) inhibitor BI-9787 freely available as a tool compound via the company’s Opnme program.
G protein-coupled receptor (GPCR) drug discovery and development specialist Confo Therapeutics NV has closed a €60 million (US$65.2 million) series B round that will fund a significant expansion of the inhouse portfolio while it continues to turn the handle on its technology platform to generate more compounds for partnering.
Zyversa Therapeutics Inc. has selected obesity and its related metabolic complications as the lead indication for its inflammasome ASC inhibitor IC-100.
Long-acting glucagon-like peptide-1 receptor (GLP-1R) agonists have shown efficacy in obesity treatment but, after discontinuation, a rapid recovery of weight is usually seen, likely due to orexigenic mechanisms involved in weight regain.
Tiximed Inc. has received IND clearance for its inhibitor of thioredoxin-interacting protein (TXNIP), TIX-100, in individuals with type 1 diabetes. TIX-100 is a potent and specific inhibitor of TXNIP.
Researchers from Shandong University and affiliated organizations have presented data from a study that aimed to assess the role of endosome-associated trafficking regulator 1 (ENTR1) in adipogenesis.
Increased life expectancy also comes with age-related diseases. But what causes one to age? Although there is no single answer, scientists at Duke-National University of Singapore (NUS) have shown in mice that interleukin-11 (IL-11) promoted aging. Blocking it improved health and lifespan.
RSS
